Armune BioScience plans to double its staff at its Ann Arbor laboratory as revenues start coming in from its cancer blood test, Apifiny.
"We expect to add 3-4 more techs by September," David Esposito, president & CEO of Armune BioScience.
The Kalamazoo-based business landed a $2.5 million Series A financing round last year. That money allowed Armune BioScience to finish developing its innovative, non-PSA blood test to aid in the early detection of prostate cancer. It launched that blood test commercially last year.
"We want to be running 1,500 tests a month by the end of the year," Esposito says.
Armune BioScience currently employs six people and is looking to hire a couple of people right now to help meet the rising demand for Apifiny. It is also raising a $2.5 million Series B, which it hopes to close this summer.
"We feel volume will drive the need for more head count," Esposito says.
Source: David Esposito, president & CEO of Armune BioScience
Writer: Jon Zemke